1. Lozada C, Steigelfest E. Osteoarthritis. Medicine Rheumatology. 2010; 15:12-23.
2. Raynauld JP, Martel-Pelletier J, Haraoui B, Pelletier JP. Chapter 25. Osteoarthritis-arthrosis short term studies: pain and function improvement in Osteoarthritis 2002, pages 294-306.
3. Garstang SV, Stitik TP. Osteoarthritis: epidemiology, risk factors, and pathophysiology. Am J Phys Med Rehabil. 2006; 85:S2–S11.
4. Tsumura H, Tamura I, Tanaka H, et al. Prescription of non-steroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopaedists in Japan. Intern Med. 2007; 46:927- 931.
5. Zhang W, Moskowitz RW, Nuki G, et al. OARSI Recommendations for the management of hip and knee osteoarthritis. part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007; 15:981-1000.
6. Bierma-Zeinstra SM, Koes BW. Risk factors and prognostic factors of hip and knee osteoarthritis. Nat Clin Pract Rheumatol. 2007; 3:78-85.
7. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007; 213:626–634.
8. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage 2004; 12 (Suppl A):S31–S33.
9. Chevalier X, Mugnier B, Bouvenot G, Chevalier X, Mugnier B, Bouvenot G. Targeted anti-cytokine therapies for osteoarthritis]. [Review] [French] Bull Acad Nationale Medecine. 2006; 190:1411–1420.
10. Roddy E, Doherty M. Changing life-styles and osteoarthritis: what is the evidence?. Best Pract Res Clin Reumatol. 2006; 20:81-97.
11. Lee YC, Shmerling RH. The benefit of nonpharmacologic therapy to treat symptomatic osteoarthritis. Curr Rheumatol Rep. 2008; 10:5-10.
12. Zhang W, Moskowitz RW, Nuki G, et al. OARSI Recommendations for the management of hip and knee osteoarthritis. part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007; 15:981-1000.
13. Zhang W, Moskowitz R, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16:137-162.
14. Bannwarth B. Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2006; 20:117-129.
15. Kobayakawa M, Uemura N. Prevention and treatment of non-steroidal anti-inflammatory drugs induced ulcers in osteoarthritis. Nippon Rinsho. 2007; 65:1857-1861.
16. Scanzello CR, Moskowitz NK, et al. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep. 2008; 10:49-56.
17. Mikhail SS, Zwar NA, Vagholkar S, Dennis SM, Day RO. Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma. Med J Aust. 2007; 187:160-163.
18. Yajima H, Yamao J, Fukui H, Takakura Y. Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopaedic outpatients: a study using logistic regression analysis. J Orthop Sci. 2007; 12:341-346.
19. Mitchell J., Warner T. Discontinuation of Vioxx. Lancet. 2004; 365:27-28.
20. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005; 365:475-481.
21. Kimmel SE, Berlin JA, Reilly M, et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005; 142:157-164.
22. Lamarque D. Pathogenesis of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs. Gastroenterol Clin Biol. 2004; 28:C18-C26.
23. Whittle BJ. Gastrointestinal effects of non-steroidal anti-inflammatory drugs. Fundam Clin Pharmacol. 2003; 17:301-313.
24. Kountouras J, Chatzopoulos D, Zavos C. Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology. 2001; 48:743-751.
25. Demir S, Yilmaz M, Koseoglu M, Akalin N, Aslan D, Aydin A. Role of free radicals in peptic ulcer and gastritis. Turkish J. Gastroenterology. 2003; 14:39-43.
26. Pohle T, Brzozowski T, Becker JC, Van Der Voort IR, et al. Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Aliment Pharmacol Ther. 2001; 15:677-687.
27. Lin J., Zhang W. et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004; 329:324-327.
28. Cepeda MS, Camargo F. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006; CD005522.
29. Towheed TE, Maxwell L, Judd M, Cotton M, Huchberg MC, Wells GA. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006; January 25 (1):CD004257.
30. Strauss EJ, Hart JA, Miller MD, Altman RD, Rosen JE. Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med. 2009; 37:1636-1644.
31. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001; 357:251-256.
32. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med.2002; 162:2113-2123.
33. McAlindon T. Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am. 2003; 29:789-801.
34. McAlindon TE, Formica M, LaValley M, et al. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med. 2004; 117:643-649.
35. Huskisson EC. Glucosamine and chondroitin for osteoarthritis. J Int Med Res. 2008; 36:1161-1179.
36. Piscoya J, Rodríguez Z, Bustamante SA, et al. Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res. 2001; 50:442-448.
37. Ahmed S, Rahman A, Hasnain A, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclo-oxygenase-2 and nitric oxide synthase-2 activity in human chondrocytes. Free Radical Biology Med. 2002; 33:1097-1105
38. Walter-Bone K. 'Natural remedies' in the treatment of osteoarthritis. Drugs & Aging. 2003; 20:517-526
39. Miller M, Mehta K, Kunte S, et al. Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial. J Inflamm. 2005; 2:11-17.
40. Frestedt JL, Walsh M, Koskowski M, Zenk J. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized, controlled pilot trial. Nutrition J. 2008; 7:9-13.
41. Cisar P. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytoher Res. 2008; 22: 518-523.
42. Frech TM, Clegg DO. The utility of nutraceuticals in the treated of osteoarthritis. Rheumatol Rep. 2007; 9:25-30.
43. Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs of the Future. 2004; 29:773-786.
44. Gámez R., Mendoza S, Más R, et al: Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res. 2000; 61:8-16.
45. Menéndez R, Mas R, Amor AM, et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res. 2001; 44:299-304.
46. Menéndez R; Más R; Pérez J et al. Oral administration of D-003, a mixture of very long chain saturated fatty acids, prevents casein-induced endogenous hypercholesterolemia in rabbits. Can J Physiol Pharmacol. 2003; 82:22-29.
47. Castaño G, Menéndez R, Mas R, et al. Effects of D-003 on lipid profile and lipid peroxidation in healthy volunteers Clin Drug Invest. 2003; 23:193-203.
48. Castaño G, Mas R, Fernández L, et al. Effects of D-003 (5-40 mg/day) on lipid profile of patients with Type II hypercholesterolemia: a Phase II clinical study. Clin Drug Invest. 2003; 23:789-802.
49. Castaño G, Mas R, Fernández L, et al. A comparison of the effects of D-003 and policosanol (5 and 10 mg/d) in patients with Type II hypercholesterolemia: a randomized, double-blinded study. Drugs Exptl Clin Res. 2005; 30:31-44.
50. Menéndez R, Mas R, Pérez Y, et al: Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can J Physiol Pharmacol. 2002; 80:13-17.
51. Pérez Y, Mas R, González RM, Jiménez S, Molina V. Effects of D-003 and policosanol on in vivo lipid peroxidation in rats. Arzn-Forsch Drug Res. 2008; 58:126-130.
52. Molina V, Arruzazabala ML, Carbajal D, Mas R. D-003, a new compound with effects on arachidonic acid metabolites. Prostagl, Leuktr, Ess Fatty Acids. 2002; 67:19-24.
53. Molina V, Noa M, Arruzazabala ML, et al. Effect of D-003, a mixture of very long chain aliphatic acids purified from sugarcane wax, on cerebral ischemia in mongolian gerbils. J Med Food. 2005; 3:21-24.
54. Carbajal D, Arruzazabala ML, Noa M, et al. Protective effect of D-003 on experimental spinal cord ischemia in rabbits. Prostagl, Leukotr & Ess Fatty Acids. 2004; 70:1-6.
55. Noa M, Mendoza S, Más R, Mendoza N. Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on CL4C-induced liver acute injury in rats. Drugs Exp Clin Res. 2002; 28:177-183.
56. Mendoza S, Noa M, Mas R, Mendoza N. Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on liver damage induced by paracetamol in rats. Int J Tissue Reaction. 2003; 25:91-98.
57. Noa M, Mendoza S, Mas R. Lack of protective effect of D003, a mixture of high molecular weight primary acids from sugar cane wax, on liver damage induced by galactosamine in rats. J Med Food. 2005; 8:343-347.
58. Noa M, Más R, Mendoza S, et al. Effects of D-003, a mixture of high molecular weight aliphatic acids from sugar cane wax, on bones from ovariectomized rats. Drugs Exptl Clin Res. 2004; 30:35-41.
59. Mendoza S, Noa M, Más R, Mendoza N. Effects of D-003 (5 – 200 mg/kg), a mixture of high molecular weight aliphatic acids from sugarcane wax, on bones and bone cell apoptosis in ovariectomized rats. Int J Tiss React. 2005; 27:213-222.
60. Mendoza S, Noa M, Mas R. A comparison of the effects of D-003, a mixture of high molecular weight aliphatic acids from sugarcane wax, and pravastatin, on bones and osteoclast apoptosis of ovariectomized rats. Drugs Exp Clin Res. 2005; 31:181-191.
61. Noa M, Mendoza S, Más R, et al. Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague Dawley rats. Drugs R&D. 2004; 5:281-290.
62. Noa M, Mendoza S, Mas R, Mendoza N, Goicochea E. Long term effects of D-003, a mixture of high molecular weight acids from sugarcane wax, on bones of ovariectomized rats: a one year study. Die Pharmazie. 2008; 63:486-488.
63. Ceballos A, Mas R, Castaño G, et al. The effect of D-003 (10 mg/day) on biochemical parameters of bone remodelling in postmenopausal women: a randomized, double-blind study. Int J Clin Pharmacol Res. 2005; 25:175-186.
64. Ceballos A, Castaño G, Mendoza S, González J, Mas R, Fernández L, Illnait J, Mesa M, Gámez R, Fernández JC, Telles R, Marrero D, Gómez M, Ruiz D, Jardines Y Effect of D-003 (10 mg/day) on the bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study. Korean J Intern Med. 2011; 26(2):168-178.
65. Efectos del D-003 sobre la calidad de vida en mujeres postmenopáusicas con densidad mineral ósea reducida. Datos de Archivo.
66. Efectos del D/003 sobre la actividad de la ciclo- oxigenasa in vitro. Datos de Archivo.
67. Mendoza S, Noa M, Valle M, Mas R, Mendoza N. Effects of D-003 on formaldehyde induced osteoarthritis in rats. Int J Pharl Sci Res. 2011 (en prensa).
68. Gámez R, Más R, Noa M, et al. Acute and subchronic oral toxicity of D-00– in rats. Toxicol Letters. 2000; 118:31-41.
69. Gámez R, Mas R, Noa M et al. Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drugs R&D. 2002; 3:375-386.
70. Gámez R, Más R, Noa M, et al. Effects of chronic administration of D-003, a mixture of sugar cane wax high molecular weight acids, in beagle–dogs. Drugs Exp & Clin Res. 2004; 30:75-88.
71. Gámez R, González JE, Rodeiro I, et al. In vivo genotoxic evaluation of D-003, a mixture of very long chain aliphatic alcohols. J Med Food. 2001; 4:85-92.
72. Gámez R, Rodeiro I, Fernández I, Acosta P. Preliminary evaluation of the cytotoxic and genotoxic potential of D-003: A mixture of very long chain fatty acids. Teratog, Carcinog, Mutagenesis. 2002; 22:175-181.
73. Rodríguez MD, Gámez R, González JE, et al. Lack of developmental toxicity of D-003: a mixture of long-chain fatty acids in rats. Fd Chem Toxicol. 2003; 41:89-93.
74. Rodríguez MD, González JE, Aleman C, et al. Evaluation of the reproductive and developmental toxicity of D-003, a mixture of long-chain fatty acids, in rats and–rabbits. Fd Chem Toxicol. 2004; 42:1977-1985.
75. Rodríguez MD, Gutiérrez A, Marrero G, García H. Perinatal/postnatal study of D-003, a mixture of long-chain fatty acids in rats. J Med Food. 2006; 9:223-230.
76. Gámez R, Noa M, Mas R, et al. Long-term carcinogenicity of D-003, a mixture of high molecular weight acids from sugarcane wax, in Sprague Dawley rats: a 24 months study. Food Chem Tox. 2007; 45:2352-2358.
77. Batlle-Gualda E, Esteve-Vives J, Piera MC, Hargreaves R, Cutts J. Adaptación transcultural al cuestionario WOMAC especifico para artrosis de rodilla y cadera. Rev Esp Reumatol. 1999; 26:38-45.
78. Angst T, Aeschlimann A, Stuki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implication for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis and Rheumatism. 2001; 45:384-391.
79. Altman R, Asch E, Bloch D, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum. 1986; 9:1039-1049.
80. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991; 34:505-514.
81. Requerimientos paran la notificación y el reporte de eventos adversos graves e inesperados en los ensayos clínicos. Regulación 45-2007, CECMED 2007, Cuba.
82. O’Brien PC, Shampo MC. Statistical considerations for performing multiple tests in a single experiment 5. Comparing two therapies with respect to several endpoints. Mayo Clin Proc. 1988; 63:1140-1143.
83. Bierma-Zeinstra SM, Koes BW. Risk factors and prognostic factors of hip and knee osteoarthritis. Nat Clin Pract Rheumatol. 2007; 3:78-85.
84. Huskisson EC. Glucosamine and chondroitin for osteoarthritis. J Int Med Res. 2008; 36:1161-1179.
85. Piscoya J, Rodríguez Z, Bustamante SA, et al. Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res. 2001, 50:442-448.
86. Ahmed S, Rahman A, Hasnain A, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclo-oxygenase-2 and nitric oxide synthase-2 activity in human chondrocytes. Free Radical Biology Med. 2002, 33:1097-1105.
87. Walter-Bone K. 'Natural remedies' in the treatment of osteoarthritis. Drugs & Aging. 2003, 20:517-526.
88. Miller M, Mehta K, Kunte S, et al. Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial. J Inflamm. 2005; 2:11-17.
89. Frestedt JL, Walsh M, Koskowski M, Zenk J. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized, controlled pilot trial. Nutrition J. 2008; 7:9-13.
90. Cisar P. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytoher Res. 2008; 22: 518-523.
91. Frech TM, Clegg DO. The utility of nutraceuticals in the treated of osteoarthritis. Rheumatol Rep. 2007; 9:25-30.
92. Rodríguez I, Illnait J, Mendoza S, Fernández L, et al. Estudio piloto de los efectos anti-inflamatorios del Abexol en sujetos con síntomas de osteoartritis. 2011 (en prensa).
93. Scanzello CR, Moskowitz NK, et al. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep. 2008; 10:49-56.
94. Pérez P, Illnait J, Fernández L, Mesa M, Fernández JC, Gámez R, Más R, Gómez M, Ruiz D, Jardines Y. Effects of D-003 (sugar cane wax acids) on the physical exercise on static bicycle test. Lat Am. J. Pharm. 2010; 29: 263-270.